BMD 001
Alternative Names: BMD-001Latest Information Update: 28 Jul 2024
At a glance
- Originator BIORCHESTRA
- Class Antidementias; Antiparkinsonians; Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Parkinson's disease
- No development reported Alzheimer's disease
- Discontinued Huntington's disease; Neurodegenerative disorders; Unspecified
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (IV, Infusion)
- 01 Jun 2023 BIORCHESTRA plans to file IND application for Alzheimer's disease in USA in 2024
- 01 Jun 2023 BIORCHESTRA plans clinical trials or BMD 001 in Alzheimer's disease in 2024